Poly (ADP-ribose) polymerase

Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors

Retrieved on: 
Monday, March 20, 2023
DNA, Index, MOA, Therapy, Neoplasm, Poly (ADP-ribose) polymerase, Nutrient, Coronavirus Scientific Advisory Board, Gynecologic Oncology (journal), Moa, Associate, MS, Blood, Downregulation and upregulation, Patient, Mass, Clinical research, HR, MTD, Growth, Fibroblast growth factor receptor, Principal, Ovarian cancer, Death, PARP, PTK, Homologous recombination, Safety, Pharmaceutical industry, Medical imaging, MD

“Having investigated novel combinations of anticancer agents, including a PARP inhibitor and an anti-angiogenic therapeutic, we have seen improved efficacy.

Key Points: 
  • “Having investigated novel combinations of anticancer agents, including a PARP inhibitor and an anti-angiogenic therapeutic, we have seen improved efficacy.
  • The Phase 1b trial is designed with a target enrollment of up to 36 patients with advanced solid tumors, focusing on specific tumor types that Allarity anticipates will be most responsive to the drug combination.
  • Researchers will analyze patient tumor samples retrospectively using Allarity’s DRP® companion diagnostics for stenoparib and dovitinib.
  • Allarity holds exclusive, global commercial rights to both dovitinib and stenoparib.

Bionano Genomics Announces Release of Version 6.2 of its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis

Retrieved on: 
Thursday, April 7, 2022
Adoption, Company, Private Securities Litigation Reform Act, SNV, Cell, Friends, Biomarker, Poly (ADP-ribose) polymerase, Genome, Informatics, Autism, PARP, Agilent Technologies, Genomics, DNA, Hospital Insurance and Diagnostic Services Act, HR, Lineagen, Automation, Forward-looking statement, HRD, Research, NGS, Doctor of Philosophy, Neoplasm, Cancer, Medicine, Health, U.S. Securities and Exchange Commission, LST, Software, Industry, Biology, Lists of publishing companies, TAI, COVID-19, OGM, GLOBE, Friends of Cancer Research, Â, Solution, SAN, LOH, Annual report, Patient, Security (finance), Medical imaging, Antibiotics

Integrated HRD genomic scarring has been introduced into this latest version of NxClinical software, developed by BioDiscovery, to measure genomic instability in a platform-agnostic way.

Key Points: 
  • Integrated HRD genomic scarring has been introduced into this latest version of NxClinical software, developed by BioDiscovery, to measure genomic instability in a platform-agnostic way.
  • Diagnostic Laboratory Services (Hawaii) will serve as the collaborator and laboratory testing site, leveraging the HRD measurement capabilities of NxClinical software.
  • We believe NxClinical 6.2 software offers an unparalleled visualization of the consequences of HRD and can streamline HRD analysis across different platforms and clinical research settings.
  • Once we have successfully integrated OGM data capabilities into NxClinical software, we expect structural variants uniquely identified by OGM to enhance the performance of our HRD analysis capabilities.

Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022

Retrieved on: 
Saturday, April 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Therapy, PARP, AML, Forward-looking statement, IND, Bone marrow, Cytarabine, AACR, Program, Poly (ADP-ribose) polymerase, American Association, CEO, DHODH, MDS, Association, American Association for Cancer Research, Safety, CMML, Annual general meeting, Inflammation, Medication, Azacitidine, PI3K, Maintenance, Business, Founder CEO, Patient, Pharmaceutical industry

Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH (DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

Key Points: 
  • Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH (DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting.
  • Rhizens poster presentations describe the preclinical characterization and differentiated features of its novel PARP inhibitor (RP12146) and preclinical data supporting the broad positioning of its DHODH inhibitor (RP7214) in AML.
  • Rhizen had earlier indicated that its PARP program had demonstrated differentiated IND enabling preclinical safety.
  • The additional preclinical data being presented at AACR 2022 suggests that this differentiated safety may be due to the lower bone marrow distribution of RP12146 and concomitantly lower haematological toxicity.

Poly (ADP-Ribose) Polymerase Inhibitors Pipeline Research Report 2021: Comprehensive Insights About 20+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 30, 2021
Genetics, Pharmaceutical, Health, Patient, News, Discovery, Talazoparib, PARP, Prostate cancer, Niraparib, Poly (ADP-ribose) polymerase, Cancer, Clinical trial, Mergers and acquisitions, Therapy, Breast cancer, Cell death, GSK, Janssen, DNA, Adult, BRCA, III, DDR, Maintenance, ADP, II, Disease, Petrochemical, Pharmaceutical industry, Fine chemical

This "Poly (ADP-ribose) polymerase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Poly (ADP-ribose) polymerase inhibitors pipeline landscape.

Key Points: 
  • This "Poly (ADP-ribose) polymerase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Poly (ADP-ribose) polymerase inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Poly (ADP-ribose) polymerase inhibitors R&D.
  • The companies which have their Poly (ADP-ribose) polymerase inhibitors drug candidates in the most advanced stage, i.e.
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Poly (ADP-ribose) polymerase inhibitors?

Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus

Retrieved on: 
Thursday, November 11, 2021
Cancer, Therapy, Breast, University of Arizona, APP, Clinical trial, Fibroblast growth factor receptor, COVID-19, National Institute, Laboratory, Fatality, NIH, NIAID, Allar, Jerusalem, Dana–Farber Cancer Institute, Severe acute respiratory syndrome coronavirus 2, Research, Social media, Forward-looking statement, Cisplatin, MBio, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doxorubicin, Patient, CEO, Disease, Degenerative disease, Goal, Northern Arizona University, PARP, Vaccine, Virus, Drug discovery, National Institutes of Health, DNA, Infection, Prostate cancer, RNA, Ixabepilone, Ovarian cancer, Renal cell carcinoma, Company, Pathogen, Antibody, Breast cancer, Center, Nasdaq, Poly (ADP-ribose) polymerase, Pharmaceutical industry

Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (British variant),

Key Points: 
  • Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (British variant),
    Allarity Therapeutics is planning to submit findings to U.S. National Institutes of Health (NIH)
    Hrsholm, Denmark (November 11, 2021) Allarity Therapeutics A/S (Allarity or the Company) today announced positive results from the further pre-clinical testing of the antiviral activity of its oral PARP inhibitor, stenoparib, against Coronavirus variant B.1.617.2 (delta variant).
  • In addition, the Company announced, on August 5, 2021, further pre-clinical tests that had shown stenoparib also inhibits SARS-Cov-2 variants, including alpha variant B.1.1.7 (British variant), beta variant B.1351 (South African variant), and gamma variant P.1 (Brazilian variant).
  • The additional pre-clinical results announced today show that stenoparib demonstrated antiviral activity inhibiting the delta variant in a dose-dependent manner in Vero E6 cells.
  • The delta variant used for the experiments carries an additional deletion in ORF7a, a rapidly spreading mutation.

Global Metastatic Breast Cancer Pipeline Insight Report 2021: Focus on 100+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, October 18, 2021
General Health, Health, Oncology, Other Health, Cytostasis, Paclitaxel, Endothelium, II, Allar, Jerusalem, SERD, Drug resistance, Metastatic breast cancer, Growth, Discovery, PARP, Roche, Therapy, Enzyme, ADC, Clinical trial, News, ESR1, CDE, Lipid, BBB, Toxicity, DRP, Poly (ADP-ribose) polymerase, Mergers and acquisitions, Neoplasm, ER, III, Medical imaging, Pharmaceutical industry, Dietary supplement

This "Metastatic Breast Cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape.

Key Points: 
  • This "Metastatic Breast Cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Breast Cancer R&D.
  • The therapies under development are focused on novel approaches to treat/improve Metastatic Breast Cancer.
  • This segment of the Metastatic Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus

Retrieved on: 
Thursday, August 5, 2021
Nau, Cisplatin, Cancer, Drug discovery, MBio, MA, Fatality, Clinical trial, Fibroblast growth factor receptor, Irofulven, Polymerase chain reaction, Lineage B.1.1.7, Doxorubicin, Infection, University of Arizona, Plaque, Therapy, Chief executive officer, Northern Arizona University, Laboratory, National Institute, Severe acute respiratory syndrome coronavirus 2, National Institutes of Health, Degenerative disease, Dana–Farber Cancer Institute, App, Breast, RNA, Pathogen, Prostate cancer, Renal cell carcinoma, Company, Research, Student, Forward-looking statement, Allar, Jerusalem, Breast cancer, PARP, Virus, National Institute of Allergy and Infectious Diseases, Patient, COVID-19, Ovarian cancer, Poly (ADP-ribose) polymerase, Ixabepilone, Social media, Center, Nasdaq, DNA, Goal, Disease, Pharmaceutical industry

The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted the tests.

Key Points: 
  • The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted the tests.
  • The concentration of stenoparib required for virus inhibition was lower in the combination study with remdesivir than in the single agent study.
  • Stenoparib is a novel small molecule (oral), targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in cancer cells.
  • Forward-looking statements include statements concerning Allaritys plans, objectives, goals, future events, performance and/or other information that is not historical information.

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Retrieved on: 
Wednesday, June 23, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Organic compounds, Cancer, PARP inhibitors, Lactams, Talazoparib, Triazoles, Antineoplastic drugs, Prostate cancer, Targeted therapy, Enzalutamide, Poly (ADP-ribose) polymerase, TALAPRO-3 Trial, Metastatic Castration-Sensitive Prostate Cancer, talazoparib, XTANDI® (enzalutamide), the Pfizer/Astellas Collaboration, Pfizer Oncology, Pfizer: Breakthroughs That Change Patients’ Lives, TALAPRO-3 TRIAL, METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, TALAZOPARIB, XTANDI® (ENZALUTAMIDE), THE PFIZER/ASTELLAS COLLABORATION, PFIZER ONCOLOGY, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).

Key Points: 
  • The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).
  • The primary endpoint of the study is radiographic progression-free survival (rPFS), and overall survival (OS) is a secondary endpoint.
  • Talazoparib is currently approved under the brand name TALZENNA for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
  • Talazoparib is being evaluated in several ongoing clinical trials in prostate cancer, as well as other novel combinations with targeted therapies in various solid tumors.

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Biology, DNA repair, Telomeres, DNA, Non-homologous end joining, DNA polymerase, Poly (ADP-ribose) polymerase, Homologous recombination, BRCA1, DNA polymerase mu, DNA polymerase lambda

These results show that Pol inhibitors exhibited exquisite selectivity and on-target activity, affecting only Pol-Mediated End Joining and not other forms of DNA repair.

Key Points: 
  • These results show that Pol inhibitors exhibited exquisite selectivity and on-target activity, affecting only Pol-Mediated End Joining and not other forms of DNA repair.
  • Dr. Graeme Smith, Chief Scientific Officer of Artios Pharma, said: This preclinical dataset further strengthens the scientific foundation of our Pol inhibitor program.
  • Artios small molecule Pol inhibitors provided nanomolar potent, selective, allosteric inhibition of the polymerase function of DNA polymerase Pol, selectively inhibiting Theta-Mediated End Joining DNA repair without targeting Non-Homologous End Joining or Homologous Recombination.
  • Sensitivity of BRCA1, Shieldin-defective tumours to Pol inhibition was confirmed in vivo laying the foundations for preclinical and clinical development.

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Biology, DNA repair, Cellular processes, Senescence, PARP inhibitor, Programmed cell death, Homologous recombination, PARP1, Poly (ADP-ribose) polymerase

This new patent completes, in a key territory, the already robust patent family protecting AsiDNA in combination with PARP inhibitors.

Key Points: 
  • This new patent completes, in a key territory, the already robust patent family protecting AsiDNA in combination with PARP inhibitors.
  • The DNA repair pathways, BRCA-dependent homologous recombination pathway and PARP pathway, are complementary and essential for tumor cell survival and proliferation.
  • If one pathway is deficient (homologous recombination by BRCA mutation) and the other is blocked by a PARP inhibitor, the tumor cell dies.
  • "This patent represents a further recognition in the strategic US market of the very original properties of AsiDNA.